Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”) announced today that its wholly owned subsidiary, IsoBev International Inc. (“IsoBev”), has executed an agreement with Brew Hub, LLC (“Brew Hub”) for the exclusive development and manufacturing of hemp, cannabis, hemp-derived, and cannabis-derived beverages in what the companies believe is among the most significant alternative beverage deals in the industry.

Brew Hub is an award-winning craft brewer and partner brewer for some of the most popular brands in craft brewing with the rare ability to maintain craft brewing standards at commercial scale.  Founded in 2012, Brew Hub operates through its taproom and pilot brewery in St. Louis, Missouri and its 100 bbl state-of-the art brewery in Lakeland, Florida.  At present, Brew Hub has a capacity of over 100,000 bbl per year with significant expansion capacity to meet future craft beer and alternative beverage demand.


Brew Hub is led by a team of experienced professionals with over 100 years of combined industry experience, including its Chief Executive Officer, Timothy Schoen, and its Chief of Brewing Operations, James “Otto” Ottolini.  Mr. Schoen is a former Vice President of AB InBev (formerly Anheuser-Busch), and his specialties include brand strategy and architecture, new product innovation, and creative development and production.

Brew Hub is majority owned by The Yucaipa Companies, LLC (“Yucaipa”), which is an American private equity firm founded in 1986.  Yucaipa provides substantial financial strength, stability, and institutional support for Brew Hub’s short- and long-term business strategies.

“We consider Brew Hub to be the preeminent ‘Partner’ brewing company in the craft beer space and to be among the few brewers able to anticipate industry trends and educate distributors and customers as those trends develop,” said Marcos Agramont, Chief Executive Officer of Isodiol.  “Tim and Otto are true visionaries in every sense of the word, and we are pleased to be working with Yucaipa, an institutional fund that brings a storied history of successful investments in grocery and hospitality.”

Mr. Schoen stated, “Isodiol is a historical frontrunner in the CBD space and has pioneered many firsts in CBD beverages, including what we believe to be the first nanoemulsified CBD ingredient that is stable as a suspended hydrocarbon in water and water-based beverages.  Many industry competitors claim to have ‘water soluble’ CBD ingredients but are disingenuous about the water solubility of naturally hydrocarbon-based CBD.  However, Isodiol is unique in its pharmaceutical understanding of molecular CBD and its delivery methods.  This specialized competency makes Isodiol a logical fit as a development partner in the alternative beverage space.”

Under the terms of the agreement, IsoBev will own the proprietary brewing formulas and intellectual property related to the Products developed with Brew Hub, and Brew Hub will provide all brewing, packaging, distribution, and selling services for the IsoBev brands internationally.

About Isodiol International Inc.

Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.

Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

Join Us On Facebook: https://www.facebook.com/IsodiolInternationalInc/
Twitter: @Isodiolintlinc

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
Ir@isodiol.com
604-409-4409

MEDIA CONTACT:
Christopher Hussey
media@isodiol.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

Click here to connect with Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) for an Investor Presentation.

Source: www.globenewswire.com

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less